Jaguar Animal Health, Inc. (NASDAQ:JAGX) Shares Shorted: Short Interest Up 67.0% in October

Jaguar Animal Health, Inc. (NASDAQ:JAGX) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 140,557 shares, a growth of 67.0% from the September 30th total of 84,156 shares. Based on an average daily volume of 4,969,953 shares, the days-to-cover ratio is currently 0.0 days. Currently, 40.7% of the shares of the company are short sold.

Jaguar Animal Health Stock Performance

JAGX opened at $1.62 on Monday. The firm has a market cap of $3.16 million, a P/E ratio of -0.00 and a beta of -0.09. The company has a current ratio of 0.69, a quick ratio of 0.40 and a debt-to-equity ratio of 0.35. The stock has a 50-day moving average of $6.46 and a 200 day moving average of $123.15. Jaguar Animal Health has a 12 month low of $1.60 and a 12 month high of $1,102.50.

Jaguar Animal Health (NASDAQ:JAGX) last issued its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($782.25) by $766.55. The company had revenue of $1.23 million during the quarter, compared to the consensus estimate of $4.24 million.

Wall Street Analysts Forecast Growth

JAGX has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Thursday, October 15th. Wall Street Zen upgraded Jaguar Animal Health to a “sell” rating in a research report on Saturday, October 10th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and commercializing plant-based pharmaceuticals for gastrointestinal disorders in animals. Its research programs are designed to address conditions affecting companion animals, livestock and other animal species, with an emphasis on therapies that support intestinal function and overall animal health.

The company’s lead product is Canalevia-CA1, a prescription product containing crofelemer. Canalevia-CA1 received conditional approval from the U.S.